CROSSTEC (03893) completes the placement of 31.104 million shares.
YiWei Group (03893) announced that all conditions stipulated in the subscription agreement have been met, and the subscription has been completed on 20...
CROSSTEC (03893) announced that all conditions stated in the placement agreement have been met, and the placement was completed on February 28, 2025. A total of 31.104 million shares (equivalent to approximately 16.67% of the enlarged issued share capital of the company after completion) were successfully placed to six subscribers at a placement price of HK$0.20 per share in accordance with the terms of the placement agreement.
Related Articles
Tencent (00700) spent 636 million Hong Kong dollars on January 5 to repurchase 1.018 million shares.
Yifan Pharmaceutical (002019.SZ): F-652, a domestically developed new indication for transplantation against host disease, approved for clinical trial.
On January 5, ES Services spent 347,100 Hong Kong dollars to repurchase 200,000 shares.
Tencent (00700) spent 636 million Hong Kong dollars on January 5 to repurchase 1.018 million shares.
Yifan Pharmaceutical (002019.SZ): F-652, a domestically developed new indication for transplantation against host disease, approved for clinical trial.
On January 5, ES Services spent 347,100 Hong Kong dollars to repurchase 200,000 shares.
RECOMMEND
Hong Kong Listed Companies’ Return To A Shares Heats Up As New “H To Shenzhen A” Case Emerges
05/01/2026
What Do The Top Ten Biopharma IPOs Of 2025 Tell Us?
05/01/2026
Asia’s Stock Markets Deliver A Strong 2025: Korea Soars 76%, Japan Tops Bubble‑Era Peak, Indonesia Records Best Year In 11 Years
05/01/2026
